These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12484028)

  • 21. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
    Ohashi N; Kodera Y; Nakanishi H; Yokoyama H; Fujiwara M; Koike M; Hibi K; Nakao A; Tatematsu M
    Int J Oncol; 2005 Sep; 27(3):637-44. PubMed ID: 16077911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
    Bamba T; Kanda T; Ohashi M; Hanyu T; Sakamoto K; Ishikawa T; Yajima K; Makino S; Tanabe T; Kosugi S; Hatakeyama K
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1695-7. PubMed ID: 16315912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intraperitoneal chemotherapy in gastric cancer patients with peritoneal dissemination].
    Hirono Y; Katayama K; Murakami M; Iida A; Yamaguchi A
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1404-9. PubMed ID: 16227738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
    J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
    Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
    Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
    Iwasaki Y; Ohashi M; Nunobe S; Iwanaga T; Iwagami S; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2009-11. PubMed ID: 19106506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
    Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical study of weekly administration of paclitaxel for advanced and metastatic gastric cancer].
    Emoto T; Yoshikawa K; Fujii M; Nezu R; Dousei T; Fujikawa M; Yoshioka Y; Naka Y; Komaki T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):809-15. PubMed ID: 12852348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity.
    Banzato A; Bobisse S; Rondina M; Renier D; Bettella F; Esposito G; Quintieri L; Meléndez-Alafort L; Mazzi U; Zanovello P; Rosato A
    Clin Cancer Res; 2008 Jun; 14(11):3598-606. PubMed ID: 18519794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
    Yamamitsu S; Kimura H; Yamada Y; Inui N; Hiyama S; Hirata K; Kimura Y; Yamaguchi K; Shirasaka T
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1405-11. PubMed ID: 17876138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
    Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of weekly administration of paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
    Hikino H; Yamada T; Hata T; Nakamura K; Sugimoto S; Kanazawa A; Tokuka A; Ozaki N
    Gan To Kagaku Ryoho; 2004 May; 31(5):759-61. PubMed ID: 15170988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.
    Nagata N; Kobayashi M; Kojima H; Kondo K; Hirabayashi N; Matsui T; Kataoka M; Takiyama W; Miyashita Y; Nakazato H; Araki K; Itoh H; Nakao A; Sakamoto J
    Hepatogastroenterology; 2005; 52(66):1905-10. PubMed ID: 16334804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers].
    Kurihara N; Kumai K; Kubota T; Furukawa T; Yamamoto T; Shimada A; Shibata S; Saikawa Y; Ogawa S; Murayama Y
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1645-8. PubMed ID: 8373238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
    Markman M; Francis P; Rowinsky E; Hoskins W
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):84-7. PubMed ID: 7597437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
    Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.